Edison-based ITC Nexus Holding Co., a global leader in hemostasis management and testing, announced Aug. 30 the acquisition of Accumetrics, which assesses patient response to antiplatelet therapies.
Terms of the transaction were not disclosed.
According to the announcement, ITC develops, manufactures and markets the Hemochron product line, which measures clotting activity for patients undergoing anticoagulation therapy. Accumetrics, of San Diego, develops, manufactures and markets the VerifyNow product line, a market-leading POC system used to measure platelet reactivity following antiplatelet therapies, including ADP receptor antagonists and aspirin.
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy